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(66%) were molecularly targeted, and 6 (8%) were immune 
checkpoint inhibitor. Thirty-six patients (3.8%) had severe 
toxicities requiring hospitalization during the first cycle. 
The overall number of toxicities requiring hospitalization 
and/or grade 4 toxicities during any cycle was 5.0%.
Conclusions The frequency of severe toxicity that needs 
to be hospitalized was unexpectedly low. The data did not 
demonstrate the need for hospitalization in the phase I tri-
als, suggesting that phase I trials in Japan could be con-
ducted in outpatient settings.
Keywords Phase I trial · Domestic guideline · Severe 
toxicity · Toxicity management
Introduction
Phase I clinical trials of oncologic drugs are conducted to 
determine the proper dosage of both single-agent and combi-
nation therapies. If the therapeutic index is very narrow, it is 
critical to evaluate the study drug toxicity in dose-escalation 
studies. Dose-limiting toxicity (DLT) is evaluated during the 
first cycle of each new dosage level for every trial participant 
to determine the maximum tolerated dose (MTD). Close 
monitoring for symptoms as well as physiological and labo-
ratory data are required to determine if DLT is observed.
Clinical trials in Japan and Western countries are carried 
out under the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use (ICH) guidelines [1]. These guidelines do not 
require hospitalization as part of phase I clinical trials. How-
ever, according to Japanese guidelines, participants in phase 
I oncology clinical trials are required to be hospitalized dur-
ing the first cycle of treatment to observe toxicity closely for 
safety reasons [2].
Abstract 
Introduction Most trials investigating new drugs around 
the world, including phase I trials, are conducted in out-
patient clinics. However, in Japan, regulatory authority 
requirements and traditional domestic guidelines often 
require hospitalization of phase I study participants.
Patients and methods Patients participating in single-agent 
phase I clinical trials at National Cancer Center Hospital 
between December 1996 and August 2014 were monitored. 
Toxicity requiring hospitalization is defined as toxicity that 
needs intensive treatment. Study designs were classified 
into three types: first-in-human (FIH) study, dose-escala-
tion study (conventional dose-escalation study to determine 
maximum tolerated dose (MTD) in Japanese patients), and 
dose-finding study (to assess safety and pharmacokinetic 
profiles up to the MTD previously determined in the West).
Results A total of 945 patients who participated in a variety 
of single-agent phase I clinical trials between December 
1996 and August 2014 were included in this study. Patients 
participated in one of three study types: dose-escalation 
(n = 582, 62%), first-in-human (n = 129, 14%), or dose-
finding (n = 234, 25%). A total of 76 study drugs were 
evaluated as part of this pool of phase I studies. Subdivided 
by mechanism of action, 20 (26%) were cytotoxic, 50 
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Because the assessment period for DLT is approxi-
mately 1 month in most phase I oncology clinical trials, in 
Japan study participants are required to be hospitalized for 1 
month. Phase I clinical oncology trial participants are gener-
ally refractory to standard treatments and usually have very 
limited options. Even though these patients have a good per-
formance status and generally good health, their life expec-
tancy is limited, and consequently, the phase I hospitalization 
requirement is sometimes in conflict with ongoing end-of-
life care. Additionally, the patient is usually charged with the 
cost of hospitalization, making a patient’s participation in the 
phase I trial burdensome with respect to time and cost. For all 
these reasons, it is very difficult to recruit patients to partici-
pate in phase I clinical trials. Furthermore, Japan’s hospitali-
zation practice makes it an outlier from standard ICH guide-
lines, limiting the globalization of Japanese oncology drug 
development.
Toxicity assessment is an essential objective of a phase 
I trial. Hyman et al. have developed a nomogram-based 
model to predict the risk of a patient developing a cycle-one 
serious drug-related toxicity (SDRT), but its practical use 
remains very limited [3]. Additionally, the type of investiga-
tional drugs upon which this model was largely derived has 
changed from cytotoxic drugs to molecularly targeted drugs 
and immune checkpoint inhibitors during the past several 
decades. Consequently, as the mechanism of action of new 
cancer drugs has changed, the toxicity profiles and timing of 
toxicity events have also changed. For example, Postel-Vinay 
et al. reported that in phase I oncology trials of molecularly 
targeted drugs, treatment interruption or discontinuation 
occurs more frequently in the second cycle rather than the 
first cycle [4].
If the frequency of severe toxicity during first cycle in 
phase I trials is low, it may be more practical to conduct trials 
in an outpatient setting or with only minimal hospitalization. 
Furthermore, minimizing or avoiding hospitalization alto-
gether may facilitate recruitment of participants and accel-
erate clinical drug development. However, to date, there has 
been no evaluation of the incidence and risk of severe toxicity 
in hospitalized patients participating in phase I clinical oncol-
ogy trials in Japan.
In this study, we surveyed severe toxicity observed in the 
phase I single-agent clinical trials conducted in our institution 




Patients who participated in single-agent phase I clini-
cal trials at National Cancer Center Hospital between 
December 1996 and August 2014 were included in this 
study. Drug type, treatment course, and toxicity were 
retrieved from medical records and databases. Severity of 
toxicity was assessed by Common Terminology Criteria 
for Adverse Events v. 4.0 [5]. Severe toxicity was classi-
fied as requiring hospitalization. Such toxicity requiring 
hospitalization is defined as follows: toxicity that requires 
intensive treatment (e.g., continuous oxygen administra-
tion, invasive procedure) and/or toxicity that requires intra-
venous intervention (e.g., fluid therapy, intravenous anti-
biotics, blood transfusion). Study designs were classified 
into three types: (1) dose-escalation (conventional dose-
escalation study to determine MTD in Japanese patients; 
FIH study was excluded); (2) first-in-human (FIH); and (3) 
dose-finding (to assess drug safety and pharmacokinetic 
profiles up to the MTD previously determined in Western 
studies).
Ethical considerations
The present study involving human subjects was approved 
by the National Cancer Center Institutional Review Board 
(2014-148). A copy of the letter from the Institutional 
Review Board is available for review by the Editor of this 
journal.
Results
A total of 945 patients participated in the phase I trial from 
December 1996 to August 2014 at the National Cancer 
Center Hospital (Tokyo, Japan). Median patient age was 
58 years (range, 18–76 years); 537 patients (57%) were 
men and 408 (43%) were women. Patients were assigned 
to receive cytotoxic drugs (n = 207, 22%), molecularly 
targeted drugs (n = 690, 73%), or immune checkpoint 
inhibitors (n = 48, 5%). Patients participated in one of 
three study types: dose-escalation (n = 582, 61%), first-in-
human (n = 129, 14%), or dose-finding (n = 234, 25%). 
Tumor types were non-small cell lung cancer (n = 248, 
28%), colorectal cancer (n = 175, 19%), sarcoma (n = 115, 
12%), esophageal cancer (n = 49, 5%), pancreatic cancer 
(n = 45, 5%), bile duct cancer (n = 36, 4%), breast cancer 
(n = 35, 4%), and gastric cancer (n = 26, 3%) (Table 1).
A total of 76 study drugs were evaluated as part of 
this pool of phase I studies. Subdivided by mechanism of 
action, 20 (26%) were cytotoxic, 50 (66%) were molecu-
larly targeted, and 6 (8%) were immune checkpoint inhibi-
tor (Table 2).
Ninety-eight patients (10.4%) developed severe tox-
icities during the first cycle; a total of 126 patients 
(13.3%) developed severe toxicities during any cycle. 
Thirty-six patients (3.8%) had severe toxicities requiring 
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hospitalization during the first cycle (Fig. 1). The over-
all number of toxicities requiring hospitalization and/or 
grade 4 toxicities during any cycle was 5.0%. In the first 
cycle, 31 patients (15.0%) who received cytotoxic drugs 
and 67 patients (9.7%) who received molecularly targeted 
drugs developed severe toxicity. However, patients who 
received immune checkpoint inhibitors did not develop 
any severe toxicity. Fourteen patients (6.8%) receiving 
cytotoxic drugs and 22 patients (3.2%) receiving molecu-
larly targeted drugs needed to be hospitalized because of 
toxicity. For patients receiving cytotoxic agents, 4 hema-
tological (1.9%) and 10 nonhematological (4.8%) toxic-
ity events required hospitalization (Table 3). For patients 
receiving molecularly targeted drugs, 3 hematological 
(0.4%) and 19 nonhematological (2.8%) toxicity events 
requiring hospitalization (Table 3).
Seventy-three patients (12.5%) in dose-escalation 
studies, 14 patients (10.9%) in FIH studies, and 11 
patients (4.7%) in dose-finding studies developed severe 
toxicity, including DLT. Twenty-seven (4.6%) dose-esca-
lation study participants, 4 (3.1%) FIH study participants, 
and 5 (2.1%) dose-finding study participants needed hos-
pitalization for toxicity (Table 4).
The observed toxicity profile included increase in 
aminotransferase (n = 39, 17.3%), neutropenia (n = 22, 
9.7%), thrombocytopenia (n = 20, 8.8%), anorexia 
(n = 13, 5.8%), and proteinuria (n = 13, 5.8%). Dur-
ing the first cycle, toxicities requiring hospitalization 
included thrombocytopenia (n = 11, 19.0%), febrile neu-
tropenia (n = 9, 15.5%), ileus/bowel obstruction (n = 5, 
8.6%), arrhythmia (n = 3, 5.2%), and pneumonia (n = 3, 
5.2%) (Table 5).
Discussion
Toxicity evaluation is one of the primary objectives of 
phase I oncology trials because such studies help define 
the recommended dose for further studies. The type 
and timing of toxicity can differ depending on a variety 
of factors including different dose levels, the class and 
Table 1  Patient characteristics
NSCLC non-small cell lung cancer, SCLC small cell lung cancer, HN 
head and neck, CUP carcinoma of unknown primary
Patients, n 945
Age, years 58 (median), 18–76 (range)
Sex, n (%)
 Male 537 (57)
 Female 408 (43)
Drug type, n (%)
 Cytotoxic 207 (22)
 Molecularly targeted 690 (73)
 Checkpoint inhibitor 48 (5)
Study type, n (%)
 Dose escalation 582 (61)
 First in human (FIH) 129 (14)
 Dose finding 234 (25)
Disease, n (%)
 NSCLC 248 (26)
 Colorectal 175 (19)
 Sarcoma 115 (12)
 Esophagus 49 (5)
 Pancreas 45 (5)
 Biliary 36 (4)
 Breast 35 (4)
 Gastric 26 (3)
 Melanoma 23 (2)
 Ovarian 23 (2)
 SCLC 20 (2)
 HN 18 (2)
 Prostate 18 (2)
 Uterine 17 (2)
 CUP 10 (1)
 Other 87 (9)
Table 2  Characteristics of study drugs and clinical studies
Study drug, n 76
Study drug, n (%)
 Cytotoxic 20 (26)
 Molecularly targeted 50 (66)
 Checkpoint inhibitor 6 (8)
Study type, n (%)
 Dose escalation 44 (57)
 First in human 8 (11)














Severe toxicity in cycle 2 or later
N = 28
Fig. 1  Patient outcomes
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mechanism of action of the study drug, and the route of 
administration [6, 7]. As new cancer targets have emerged 
over the past several decades, there is now a much wider 
array of investigational drugs with new mechanisms of 
action. As such, classical a “3 + 3 design” may be not 
sufficient to evaluate toxicities in the current era [7–9].
A modeling approach using toxicity data from 3104 
participants in 127 phase I trials between 2000 and 2010 
to estimate the risk of SDRT has been reported [3]. In this 
study, SDRT was defined as grade ≥4 hematological tox-
icity or grade ≥3 nonhematological toxicity attributed, at 
least possibly, to study drug(s). The parameters used in 
this empirical model to predict SDRT risk included per-
formance status, white blood cell count, creatinine clear-
ance, serum albumin, alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, number of study 
drug(s), class of study drug, dose level, and constitutional 
symptoms. Although the resulting nomogram can be use-
ful in predicting a patient’s risk for SDRT at the time of 
enrollment, its usage remains limited. In our study, we 
assessed every toxicity observed after study enrollment 
regardless of study drug causality. Frequent severe tox-
icities were increased aminotransferase, neutropenia, 
and thrombocytopenia. Toxicities requiring hospitaliza-
tion were hematological, such as thrombocytopenia and 
febrile neutropenia, a tendency similar to that previously 
observed [3]. Toxicity requiring hospitalization was 
more frequent in studies involving cytotoxic drugs com-
pared to those using molecularly targeted drugs (15.9% 
vs. 9.4%, respectively) (Table 3). This result is consist-
ent with other reported observations that molecularly 
targeted drugs are negatively correlated with SDRT. In 
this study, we did not observe severe toxicity in patients 
who received immune checkpoint drugs. However, there 
are some reports of severe toxicity associated with this 
class of drugs [10], and the lack of observed severe toxic-
ity in our study may be because only a small number of 
patients received immune checkpoint drugs compared to 
the other drug classes.
Severe toxicity was observed in 10.4% of all partici-
pants during the first cycle and in 3.2% of all participants 
during the second or later cycles, a result similar to a 
previous report. Thus, it is important to observe toxic-
ity carefully not only during the first cycle but in later 
cycles as well. We observed that 3.8% of participants 
experienced severe toxicity requiring hospitalization, and 
that 5.0% of all participants experienced either grade 4 
toxicity or severe toxicity requiring hospitalization. This 
frequency was unexpectedly low and was independent of 
drug class. This overall low severe toxicity rate suggests 
that toxicity can be safely monitored in an outpatient set-
ting and that hospitalization during the entire clinical 
study period is not necessary in most studies. Nonethe-
less, toxicity observation is still important after the DLT 
evaluation period. Moreover, it is important to continue 
careful monitoring for toxicity throughout the course of 
a phase I trial of immune checkpoint inhibitors because 
such drugs may have delayed adverse effects [10].
Table 3  Toxicity by drug type
Drug type
Cytotoxic, n = 207 Molecularly targeted, 
n = 690
Checkpoint inhibitor, n = 48
Number of severe toxicities in cycle 1, n (%) 31 (15) 67 (9.7) 0 (0)
Hospitalization required, n (%)
 Hematological 14 (6.8) 4 (1.9) 22 (3.2) 3 (0.4) 0 (0)
 Nonhematological 10 (4.8) 19 (2.8)
No hospitalization required, n (%)
 Hematological 17 (8.2) 8 (3.9) 45 (6.5) 6 (0.9) 0 (0)
 Nonhematological 9 (4.3) 39 (5.7)
Table 4  Toxicity by study type
FIH first-in-human
Dose escalation, n = 582 FIH, n = 129 Dose finding, n = 234
Number of severe toxicities in cycle 1, n (%) 73 (12.5) 14 (10.9) 11 (4.7)
Required hospitalization, n (%) 27 (4.6) 4 (3.1) 5 (2.1)
Required hospitalization and/or G4, n (%) 34 (5.8) 7 (5.4) 6 (2.6)
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Table 5  Adverse events (AEs) observed during trial
Any AEs AEs requiring  
hospitalization 
in cycle 1
n % n %
Aminotransferase increased 39 17.3 4 6.9
Neutropenia 22 9.7 0 0.0
Thrombocytopenia 20 8.8 11 19.0
Anorexia 13 5.8 1 1.7
Proteinuria 13 5.8 0 0.0
Nausea 10 4.4 0 0.0
Febrile neutropenia 9 4.0 9 15.5
Anemia 7 3.1 2 3.4
Malaise 7 3.1 1 1.7
CPK increased 5 2.2 0 0.0
Diarrhea 5 2.2 0 0.0
Ileus 5 2.2 5 8.6
Rash 5 2.2 1 1.7
T-Bil increased 5 2.2 0 0.0
WBC decreased 5 2.2 0 0.0
Hypertension 4 1.8 0 0.0
GGT increased 4 1.8 0 0.0
Mucositis 4 1.8 1 1.7
Vomiting 4 1.8 2 3.4
Arrhythmia 3 1.4 3 5.2
Pneumonitis 3 1.4 3 5.2
Colitis 2 0.9 2 3.4
Hypoxia 2 0.9 2 3.4
Infection 2 0.9 2 3.4
CIPN 2 0.9 0 0.0
QTc prolonged 2 0.9 0 0.0
Unacceptable by patients 2 0.9 0 0.0
AMY increased 1 0.4 0 0.0
Constipation 1 0.4 1 1.7
Creatinine increased 1 0.4 0 0.0
Dehydration 1 0.4 1 1.7
Drug fever 1 0.4 0 0.0
Dry skin 1 0.4 0 0.0
DVT 1 0.4 0 0.0
Dyspnea 1 0.4 1 1.7
ECG abnormality 1 0.4 0 0.0
Edema 1 0.4 0 0.0
Hearing disorder 1 0.4 0 0.0
Hyperglycemia 1 0.4 1 1.7
Hypoalbuminemia 1 0.4 0 0.0
Hypotension 1 0.4 1 1.7
Lipase increased 1 0.4 0 0.0
Muscle weakness, extremity lower 1 0.4 0 0.0
Perforation 1 0.4 1 1.7
Pericardial effusion 1 0.4 1 1.7
Pleural effusion 1 0.4 1 1.7
AEs adverse events, CPK creatinine phosphokinase, T-Bil total biliru-
bin, WBC white blood cell, GGT gamma-glutamyltransferase, CIPN 
chemotherapy-induced peripheral neuropathy, AMY amylase, ECG 
electric cardiogram, DVT deep vein thrombosis
Table 5  continued
Any AEs AEs requiring  
hospitalization 
in cycle 1
n % n %
Pneumonia 1 0.4 1 1.7
Pyrexia 1 0.4 0 0.0
Uric acid increased 1 0.4 0 0.0
Total 226 100 58 100
The frequency of toxicity by study types was similar 
in both the dose-escalation and FIH studies (12.4% and 
10.4%, respectively) (Table 4), possibly because FIH stud-
ies start at much lower dosage levels (e.g., 0.1 LD10 of 
mice) compared to the doses used in dose-escalation stud-
ies. Severe toxicity in dose-finding studies was low (4.7%), 
likely because the dose level in these studied may not 
reach the MTD. Consequently, in phase I oncology dose-
escalation and dose-finding studies, hospitalization during 
the first cycle should not be mandatory. In contrast, in FIH 
studies conducted to determine MTD, careful observation 
is required because the drug’s toxicity profile is not well 
characterized, and hospitalization is one option to ensure 
patient safety. In FIH studies in Japan for drugs studied in 
earlier Western trials, it can be useful to use the Western 
clinical data to design phase I trials that reduce the risk of 
severe toxicity because it has been observed that the both 
the MTD and DLT frequency tends to be very similar 
between Western and Japanese patients [11].
The present study has some limitations. It is a retrospec-
tive study, and there is no analysis by design (e.g., conven-
tional “3 + 3” design, accelerated titration design, etc.) or 
by dosage levels. Of particular note, there is no standardi-
zation regarding the type of toxicity requiring hospitaliza-
tion in Japan compared to other countries. We employed 
the definition described in the Methods, although it should 
be noted that hematological toxicity can be managed in an 
outpatient setting by blood transfusion with close monitor-
ing in some cases. An effort between clinical investigators, 
regulatory authority, and other key stakeholders to identify 
a consensus definition of “toxicity requiring hospitaliza-
tion” is warranted.
Conclusion
Our results indicate that there is a low rate of severe tox-
icity requiring hospitalization in phase I oncology trials in 
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Japan. Consequently, the conventional approach requiring 
participants to be hospitalized during the first cycle of the 
phase I trial is not necessary. Rather, the outpatient setting 
should be considered for phase I clinical trials in Japan.
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